Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yuko Matsumoto-Mishima"'
Autor:
Kiyohiko Hatake, Kiyotsugu Kojima, Masahiro Yokoyama, Hiroaki Asai, Daisuke Ennishi, Suzuka Asai, Kengo Takeuchi, Yasuhito Terui, Yuko Matsumoto-Mishima, Natsuhiko Sugimura, Yuji Mishima
Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b60b8d491aa301bdf35dec127985fb
https://doi.org/10.1158/1078-0432.22439626.v1
https://doi.org/10.1158/1078-0432.22439626.v1
Autor:
Kiyohiko Hatake, Kiyotsugu Kojima, Masahiro Yokoyama, Hiroaki Asai, Daisuke Ennishi, Suzuka Asai, Kengo Takeuchi, Yasuhito Terui, Yuko Matsumoto-Mishima, Natsuhiko Sugimura, Yuji Mishima
Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4360bd877c3fe2326dcae2361eb06986
https://doi.org/10.1158/1078-0432.c.6517063
https://doi.org/10.1158/1078-0432.c.6517063
Autor:
Suzuka Asai, Masahiro Yokoyama, Natsuhiko Sugimura, Daisuke Ennishi, Kiyotsugu Kojima, Yuji Mishima, Yasuhito Terui, Kengo Takeuchi, Hiroaki Asai, Yuko Matsumoto-Mishima, Kiyohiko Hatake
Publikováno v:
Clinical Cancer Research. 15:3624-3632
Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2eac4c289fcc6cde0fae1a8366d1a71
https://doi.org/10.1158/1078-0432.ccr-08-1536
https://doi.org/10.1158/1078-0432.ccr-08-1536
Autor:
Yuko Matsumoto-Mishima, Masaki Mori, Kiyohiko Hatake, Muneo Yamada, Junichiro Watanabe, Nobuyuki Mizunuma, Yukihito Ishizaka, Yuji Mishima, Misa Katsuyama, Hirotoshi Hayasawa, Yasuhito Terui, Kazuma Ikeda
Publikováno v:
CancerSpectrum Knowledge Environment. 94:1020-1028
Background: Attachment of leukemic cells to vascular endothelial cells induces the vascular endothelial cells to release endothelial cell-derived interleukin 8 (endothelial IL-8), which then induces leukemic cells to undergo apoptosis. NB4, a human p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b8d2b5aff36102d5a047019550fc40
https://doi.org/10.1093/jnci/94.13.1020
https://doi.org/10.1093/jnci/94.13.1020
Autor:
Yuko Matsumoto-Mishima, Yasuhito Terui, Kiyohiko Hatake, Natsuhiko Sugimura, Akiko Rokudai, Ryoko Kuniyoshi, Yuji Mishima
Publikováno v:
Cancer science. 98(3)
CD13/aminopeptidase-N (CD13/APN) is an important regulator of angiogenesis where its expression on activated blood vessels is induced by angiogenic signals. A previous study demonstrated that angiogenesis is suppressed under the presence of high conc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b7a6ad94f4324148bab8b44e47fc7d5
https://pubmed.ncbi.nlm.nih.gov/17270026
https://pubmed.ncbi.nlm.nih.gov/17270026
Autor:
Yuko Matsumoto-Mishima, Yuji Mishima, R Utsubo-Kuniyoshi, Yasuhito Terui, Kengo Takeuchi, Satoshi Matsusaka, Kiyohiko Hatake
Publikováno v:
Blood Cancer Journal
C-terminal mutations of CD20 constitute part of the mechanisms that resist rituximab therapy. Most CD20 having a C-terminal mutation was not recognized by L26 antibody. As the exact epitope of L26 has not been determined, expression and localization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc81045fdaa1c6879298d46f684665e8
https://doi.org/10.1038/bcj.2011.11
https://doi.org/10.1038/bcj.2011.11